ISRCTN52806782进行中（未招募）2 期
Validation of a novel composite of skin biomarkers as a primary outcome measure for evaluating the safety of treatments for atopic dermatitis study 2: a randomised controlled trial (phase 2) comparing the effects of crisaborole 2% ointment to betamethasone valerate 0.025% cream on skin structure and function in participants with atopic dermatitis.
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Volunteers with AD, defined according to the UK working party diagnostic criteria, not currently undergoing, or requiring, active drug treatment at baseline (visit 1)
- •2. Male or female aged 18-64 years old at baseline (Visit 1)
- •3. Volunteer understands the purpose, modalities and potential risk of the trial
- •4. Participants able to read and understand English
- •5. Participants willing to sign the informed consent
排除标准
- •1. Participants with a known allergy/hypersensitivity to any of the excipients of the trial preparations.
- •2. Participants with acne, suntan, birth marks, multiple nevi, tattoos, blemishes or dense body hair that obstruct the test areas.
- •3. Investigator assessment of eczema severity at the measurement (anatomical) sites on the volar forearm and cheek is almost clear or greater (score =1) based on the Investigators static global assessment (ISGA) scale at screening and baseline. At the start of the study the skin of the volar forearm and cheek measurement sites will therefore be clear (0) of the signs of eczema.
- •4. Investigator assessment of eczema severity at the measurement (anatomical) sites on the antecubital fossae is moderate or severe (score =3) based on the Investigators static global assessment (ISGA) scale at screening and baseline. At the start of the study the skin of the antecubital fossa measurement sites will therefore be clear (0) of the signs of eczema, almost clear (1) or mild (2).
- •5. Participants with a condition that in the opinion of the investigator contradicts participation in the study.
- •6. Pregnant female participants; breastfeeding female participants; and female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
- •7. Use of any topical product on the test areas within 7 days prior to Baseline/Day 1, including cosmetic moisturizers and sunscreen. Participants using any topical products on the test areas within 7 days at the screening visit will be eligible if they are willing and able to wash-out these products for 7 days in total and for the duration of the trial. Such participants will be potentially eligible at screening and will be confirmed as eligible if adequate washout is confirmed at visit 1. Use of moisturizers and/or sunscreen is permitted during the study to manage dry skin and sun exposure in areas surrounding but not on or overlapping the test areas.
- •8. Participants who have used a tanning bed within 28 days of baseline (visit 1). Participants who have used a sunbed within 28 days at the screening visit will be eligible if they are willing and able to wash-out for 28 days in total and for the duration of the trial. Such participants will be potentially eligible at screening and will be confirmed as eligible if adequate washout is confirmed at visit 1.
- •9. Participants who have used any medication that could interfere with the trial aim prior to the start of the study (baseline/visit 1). Participants using such medication at the screening visit will be eligible if they are willing and able to wash-out these treatments for the applicable washout period as defined by in section 8.8 ‘Prior and Concomitant Medication’ and for the duration of the trial. Such participants will be potentially eligible at screening and will be confirmed as eligible if adequate washout is confirmed at visit 1.
- •10. Participants currently participating in another interventional clinical trial.
- •11. Volunteer is incapable of giving fully informed consent.
- •12. Participants judged by the PI to be inappropriate for the trial.
研究者
相似试验
进行中（未招募）
1 期
Skin bioMARkers for atopic eczema Therapy evaluatioatopic eczema (synonym atopic dermatitis) and the adverse treatment side effect epidermal atrophyMedDRA version: 21.1Level: LLTClassification code 10003641Term: Atopic eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10040799Term: Skin atrophySystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-002643-23-GBSheffield Teaching Hospitals NHS Foundation Trust37
已完成
2 期
Skin bioMARkers for Atopic Eczema Therapy EvaluationAtopic Eczema/Dermatitis (Non-Specific)NCT04194814Sheffield Teaching Hospitals NHS Foundation Trust37
已完成
不适用
TRANSlational Cancer Oesophagus Gefitinib study (TRANS-COG)CancerISRCTN32435732niversity of Aberdeen (UK)300
已完成
不适用
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other ParkinsonismDementia With Lewy BodiesProgressive Supranuclear PalsyCorticobasal DegenerationParkinsonismParkinson DiseaseMultiple System AtrophyNCT04518059University Hospitals Cleveland Medical Center184
尚未招募
1 期
Characteristics of biomarker on dermal sensitization for myocardial ischemia-reperfusion injurymyocardial ischemia reperfusion injuryITMCTR2024000180the Affiliated Hospital of Shaanxi University of Chinese Medicine